Barclays analyst Matt Miksic initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $22 price target The timing for the company’s entry into transcatheter aortic valve replacement “could not look better,” the analyst tells investors in a research note. The firm says the market is now “deeply entrenched” between the preference for balloon-expandable valve and the need for hemodynamics in smaller valves. It believes Anteris ‘ DurAVR can provide balloon-expandable valve delivery for all valve sizes, and meet the growing demand for valve replacement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVR:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
